問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Urology

Digestive System Department

Division of Hematology & Oncology

Division of Pediatrics

Kaohsiung Municipal Ta-Tung Hospital

Division of Hematology & Oncology

Taipei Veterans General Hospital

更新時間：2023-09-19

杜政勳Du, Jeng-Shiun
  • Principal Investigator
  • Clinical Trial Experience (year) 8 years 3 個月

Recruiting Trial

91Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

杜政勳

List

124Cases

2021-03-17 - 2025-06-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-10-20 - 2022-04-28

Phase III

A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

  • Condition/Disease

    Primary Immune Thrombocytopenia(ITP)

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2021-04-01 - 2022-09-30

Phase III

An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

  • Condition/Disease

    Primary Immune Thrombocytopenia

  • Test Drug

    Rozanolixizumab

Participate Sites
8Sites

Not yet recruiting8Sites

2019-12-01 - 2022-12-31

Phase I

A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

  • Condition/Disease

    Solid Tumor/Non-Hodgkin's Lymphoma

  • Test Drug

    ATG-019

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

1 9 10 11 12 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB